Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Chronic kidney disease

HIV and renal AA amyloidosis in intravenous drug users

Nature Reviews Nephrology volume 9, page 64 (2013)Cite this article

Access through your institution
Buy or subscribe

Over a 10-year period, amyloid A (AA) amyloidosis was the predominant cause of progressive renal disease in patients with current or prior intravenous drug use and chronic kidney disease who underwent renal biopsy in Frankfurt, Germany, being responsible for 50% of cases. 67% of the patients with AA amyloidosis were HIV positive compared with 17% of the patients without AA amyloidosis (P = 0.036). The researchers suggest that the increased frequency and duration of infections and the immunosuppression in intravenous drug users with HIV might promote the development of AA amyloidosis.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPER

  1. Jung, O. et al. Renal AA-amyloidosis in intravenous drug users—a role for HIV-infection? BMC Nephrol. doi:10.1186/1471-2369-13-151

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

HIV and renal AA amyloidosis in intravenous drug users. Nat Rev Nephrol 9, 64 (2013). https://doi.org/10.1038/nrneph.2012.270

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrneph.2012.270

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing